Montelukast Accord (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, which is activated by leukotrienes released during allergic and inflammatory responses. By inhibiting this receptor, the drug reduces bronchoconstriction, mucus production, vascular leakage, and recruitment of inflammatory cells, thereby improving airway patency and reducing allergic symptoms.

The dosage of Montelukast Accord is individualized by the prescribing clinician based on the patient’s age, weight, indication and overall treatment plan. Healthcare providers determine the appropriate strength, frequency and duration, and patients should follow the prescription label exactly.

Safety data for montelukast in pregnancy are limited; it should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Montelukast is excreted in breast milk in small amounts, so breastfeeding mothers should discuss risks and alternatives with their physician.

To request Montelukast Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast and inhaled corticosteroids target different aspects of airway disease. Montelukast blocks leukotriene‑mediated inflammation and is taken orally once daily, making it useful for patients who cannot tolerate inhalers or need additional control. Inhaled corticosteroids act directly on airway epithelium to suppress a broader range of inflammatory mediators and remain the first‑line therapy for many asthma patients.

Montelukast Accord tablets should be stored below 25 °C (77 °F) in their original container, protected from moisture, heat and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Montelukast Accord is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it is not intended for crushing, chewing, or splitting unless specifically advised by a healthcare professional.

Serious adverse reactions, although rare, include angioedema, severe neuropsychiatric events such as agitation, depression or suicidal thoughts, and hepatic injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, mood changes, jaundice, or any signs of an allergic reaction.

Montelukast Accord is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should also be avoided in patients who require immediate relief of acute bronchospasm, as it is not a rescue medication. Clinicians should assess each patient’s medical history before initiating therapy.